DyNAbind and OMass Therapeutics enter collaboration agreement
April 17, 2019

Dresden, Germany, 16.04.2019 – DyNAbind GmbH and OMass Therapeutics have entered a collaboration for the discovery of new fragment- and small…

Read More
OMass Therapeutics Expands its Senior Leadership Team
November 27, 2018

Dr Ali Jazayeri – Chief Scientific Officer Dr Giles Brown – VP, Medicinal Chemistry Dr Hsin Loke – VP, Head of…

Read More
OMass Therapeutics Announces £14 Million Series A Financing to Build a Pipeline of Proprietary Medicines
November 21, 2018

– Developing novel medicines using structural mass spectrometry – Oxford, 20 November 2018 – OMass Therapeutics (“OMass”), a biopharmaceutical company using…

Read More
OMass Therapeutics is Expanding its Team
November 20, 2018

Oxford, 20 November 2018 – OMass Therapeutics (“OMass”), a biotechnology company using structural mass spectrometry to discover novel medicines is expanding…

Read More